InvestorsHub Logo
Followers 14
Posts 733
Boards Moderated 0
Alias Born 12/09/2013

Re: None

Wednesday, 04/13/2022 8:43:47 AM

Wednesday, April 13, 2022 8:43:47 AM

Post# of 2958
https://www.bloomberg.com/news/articles/2022-04-13/shionogi-falls-most-in-decade-on-birth-defect-risk-of-covid-pill

"The pill’s [shionogi's covid antiviral] chance of commercial success fell to 5% from 50% after the report tying it to birth defects, which may make it less competitive, said Stephen Baker, an equities analyst at Jefferies & Co."

also

" Demand for drugs to treat Covid is fierce as the world transitions to an endemic state and the focus shifts to easy-to-take medications."

--------------
Enanta's covid candidate EDP-325 is expected to finish it's Phase 1 MAD and SAD dosing in the 2nd quarter and commence phase 2 in Q3
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News